- Home
- RARE vs SRPT Comparison
RARE vs SRPT Comparison
Compare RARE & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | SRPT |
|---|---|---|
| Founded | 2010 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RARE | SRPT |
|---|---|---|
| Price | $21.26 | $16.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 28 |
| Target Price | ★ $66.32 | $25.48 |
| AVG Volume (30 Days) | 2.0M | ★ 2.1M |
| Earning Date | 05-04-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.31 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $673,000,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $13.40 | N/A |
| Revenue Next Year | $42.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.13 | 15.58 |
| 52 Week Low | $18.41 | $10.42 |
| 52 Week High | $40.54 | $103.32 |
Technical Indicators
Market Signals| Indicator | RARE | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 38.61 |
| Support Level | $19.61 | $15.51 |
| Resistance Level | $25.46 | $19.55 |
| Average True Range (ATR) | 0.98 | 0.81 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 39.06 | 29.66 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.